XtalPi Holdings, a company focused on accelerating drug development, has increased the success rate of chemical experiments from 20-30% to 90% through the use of a specially designed AI model, according to SCMP.
“There are many good opportunities [for artificial intelligence] in vertical fields. In pharmaceuticals, we see great potential for applying LLM,” commented XtalPi’s Chief Scientific Officer Zhang Peiyu.
According to his forecasts, the integration of robotics and artificial intelligence will reduce drug discovery timelines from four years to two.
XtalPi was founded in 2014 by quantum physicists from the Massachusetts Institute of Technology. A year later, the firm established a research and development base in Shenzhen, China.
The company has become a key player in AI-driven drug development, serving nearly 80% of major pharmaceutical firms worldwide.
In XtalPi’s automated chemical laboratory, around 200 AI-powered robots are operational.
Despite significant achievements, Peiyu noted that China lags behind the United States in top-tier innovations and fundamental research in biomedicine.
Back in December, researchers from the Chinese University of Hong Kong developed an AI model for addressing clinical tasks in ophthalmology, such as screening and diagnosing diseases.
Previously, scientists created a “smart throat” system, enabling stroke survivors and patients with dysarthria to regain natural speech.